Community-associated meticillin-resistant Staphylococcus aureus

Lancet. 2010 May 1;375(9725):1557-68. doi: 10.1016/S0140-6736(09)61999-1. Epub 2010 Mar 5.

Abstract

Meticillin-resistant Staphylococcus aureus (MRSA) is endemic in hospitals worldwide, and causes substantial morbidity and mortality. Health-care-associated MRSA infections arise in individuals with predisposing risk factors, such as surgery or presence of an indwelling medical device. By contrast, many community-associated MRSA (CA-MRSA) infections arise in otherwise healthy individuals who do not have such risk factors. Additionally, CA-MRSA infections are epidemic in some countries. These features suggest that CA-MRSA strains are more virulent and transmissible than are traditional hospital-associated MRSA strains. The restricted treatment options for CA-MRSA infections compound the effect of enhanced virulence and transmission. Although progress has been made towards understanding emergence of CA-MRSA, virulence, and treatment of infections, our knowledge remains incomplete. Here we review the most up-to-date knowledge and provide a perspective for the future prophylaxis or new treatments for CA-MRSA infections.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Toxins / genetics
  • Community-Acquired Infections / diagnosis
  • Community-Acquired Infections / epidemiology
  • Community-Acquired Infections / therapy
  • Drainage
  • Exotoxins / genetics
  • Humans
  • Leukocidins / genetics
  • Methicillin-Resistant Staphylococcus aureus / pathogenicity*
  • Nasal Cavity / microbiology
  • Staphylococcal Infections / diagnosis
  • Staphylococcal Infections / epidemiology
  • Staphylococcal Infections / genetics
  • Staphylococcal Infections / therapy*

Substances

  • Anti-Bacterial Agents
  • Bacterial Toxins
  • Exotoxins
  • Leukocidins
  • Panton-Valentine leukocidin